Santhera Pharmaceuticals Holding AG

SANN

CH1276028821

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:41 11/07/2024 BST			5-day change	1st Jan Change
8.37 ^CHF	+1.82%		-0.59%	-14.68%

06-19	Transcript : Santhera Pharmaceuticals Holding AG - Special Call
06-18	Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension	MT

Santhera Pharmaceuticals Approves New Members of the Compensation Committee

April 22, 2020 at 11:39 am

Santhera Pharmaceuticals confirmed Elmar Schnee and Patrick Vink as members of the Compensation Committee at the Annual General Meeting held on April 22, 2020.

Latest news about Santhera Pharmaceuticals Holding AG

Transcript : Santhera Pharmaceuticals Holding AG - Special Call	06-19
Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension	06-18	MT
Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024	04-25
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	04-25	MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	04-17	MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	03-27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	03-27	CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	02-21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	02-14	MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	01-15	CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	01-12	MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	01-12	MT
Swiss Equities Edge Down After Central Banks Buzz	12-18	MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug	12-18	MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers	12-07	MT
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer	12-07	CI
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy	27/10/23	CI
Santhera, Catalyst Pharmaceuticals Secure US FDA Nod for Rare Neuromuscular Disease Drug	27/10/23	MT
Catalyst Pharmaceuticals Says Santhera's Agamree Gains FDA Approval for Duchenne Muscular Dystrophy Treatment	26/10/23	MT
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval	26/10/23	DJ
US FDA approves Santhera's drug for rare muscular dystrophy	26/10/23	RE
US FDA approves Santhera's Duschenne drug	26/10/23	RE
Santhera Gets Positive Opinion From European Medicines Agency's Committee for Duchenne MD Drug	13/10/23	MT

Chart Santhera Pharmaceuticals Holding AG

Duration

Period

Chart Santhera Pharmaceuticals Holding AG

More charts

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Sector

Pharmaceuticals

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.22 CHF

Average target price

34.5 CHF

Spread / Average Target

+319.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SANTHERA PHARMACEUTICALS HOLDING AG	-14.68%	84.23M
MERCK KGAA	+6.42%	70.2B
KYOWA KIRIN CO. LTD.	+30.84%	10.12B
YUHAN CORPORATION	+28.34%	4.83B
SK BIOPHARMACEUTICALS CO., LTD.	-20.02%	4.53B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+18.94%	3.59B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+22.06%	2.18B
BETTA PHARMACEUTICALS CO., LTD.	-36.80%	1.8B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-42.53%	1.74B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Pharmaceuticals

Santhera Pharmaceuticals Approves New Members of the Compensation Committee

Latest news about Santhera Pharmaceuticals Holding AG

Chart Santhera Pharmaceuticals Holding AG

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals